COVID-19 vaccine booster induces a strong CD8+ T cell response against Omicron variant epitopes in HLA-A*02:01+ individuals

The >30 mutated residues in the Omicron spike protein have led to its rapid classification as a new SARS-CoV-2 variant of concern. As a result, Omicron may escape from the immune system, decreasing the protection provided by COVID-19 vaccines. Preliminary data shows a weaker neutralizing antibody response to Omicron compared to the ancestral SARS-CoV-2 virus, which can be increased after a booster vaccine. Here, we report that CD8+ T cells can recognize Omicron variant epitopes presented by HLA-A*02:01 in both COVID-19 recovered and vaccinated individuals, even 6 months after infection or vaccination. Additionally, the T cell response was stronger for Omicron variant epitopes after the vaccine booster. Altogether, T cells can recognize Omicron variants, especially in vaccinated individuals after the vaccine booster. One-Sentence Summary CD8+ T cells response against Omicron variant epitopes is stronger after the vaccine booster.

[1]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, Cell.

[2]  A. Sigal,et al.  SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.

[3]  S. Hoehl,et al.  Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.

[4]  G. Screaton,et al.  Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum , 2021, The Lancet.

[5]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[6]  C. Szeto,et al.  The pockets guide to HLA class I molecules , 2021, Biochemical Society transactions.

[7]  K. Good-Jacobson,et al.  Advances in understanding the formation and fate of B-cell memory in response to immunization or infection , 2021, Oxford open immunology.

[8]  T. Jin,et al.  Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants , 2021, Cell Reports.

[9]  P. Österlund,et al.  Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans , 2021, medRxiv.

[10]  A. Ciabattini,et al.  Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine , 2021, medRxiv.

[11]  C. Szeto,et al.  CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses , 2021, Immunity.

[12]  Y. Kawaoka,et al.  Antibody titers against SARS-CoV-2 decline, but do not disappear for several months , 2021, EClinicalMedicine.

[13]  C. Szeto,et al.  The presentation of SARS-CoV-2 peptides by the common HLA-A∗02:01 molecule , 2021, iScience.

[14]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[15]  Xuejun Ma,et al.  T and B cell Epitope analysis of SARS‐CoV‐2 S protein based on immunoinformatics and experimental research , 2020, Journal of cellular and molecular medicine.

[16]  S. Ray,et al.  Durable SARS-CoV-2 B cell immunity after mild or severe disease , 2020, medRxiv.

[17]  D. Burton,et al.  Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2020, bioRxiv.

[18]  R. Cox,et al.  Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.

[19]  P. Doherty,et al.  Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.

[20]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[21]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[22]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[23]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[24]  B. Ni,et al.  Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV , 2009, BMC Immunology.

[25]  Steven J Mack,et al.  Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. , 2008, Human immunology.